



EFFECTIVE JANUARY 1, 2021

Permanent J-Code Now Available

J9144

injection, daratumumab, 10 mg and hyaluronidase-fihj

The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code exclusive to DARZALEX FASPRO™. J9144 will replace the use of miscellaneous HCPCS codes.

Please be sure systems are updated prior to the effective date of **January 1, 2021**.



**janssen
CarePath**

For more information about DARZALEX FASPRO™, please visit [JanssenCarePath.com](https://www.JanssenCarePath.com).

HCPCS=Healthcare Common Procedure Coding System.

This document is presented for informational purposes only and is not intended to provide reimbursement or legal advice, nor does it promise or guarantee coverage, levels of reimbursement, payment, or charge. Similarly, all HCPCS codes are supplied for informational purposes only and represent no statement, promise, or guarantee by Janssen Biotech, Inc., that these codes will be appropriate or that reimbursement will be made. It is not intended to increase or maximize reimbursement by any payer. Laws, regulations, and policies concerning reimbursement are complex and are updated frequently. While we have made an effort to be current as of the issue date of this document, the information may not be as current or comprehensive when you view it. We strongly recommend you consult the payer organization for its reimbursement policies.

DARZALEX FASPRO™ and its logo are registered trademarks of Janssen Biotech, Inc.

© Janssen Biotech, Inc. 2020 All rights reserved. 11/2020 cp-188186v1

